Psychedelics making it today to the top of USA ๐บ๐ฒ health institutions: @NIH
Joshua Gordon started emphasizing NIH's #mechanistic funding focus
4k attendees in 21 time zones ๐๐๐
Franz Vollenweider ๐จ๐ญ ๐จโ๐ฌ summarizing history and neurobiology ๐ง
Molecular mechanisms focused on 5HT2A receptor and downstream Glutamate release
Sophisticated psychological model summarized nicely in one slide ๐
Alpha power drop highlighted as most reliable brain signature of psychedelics.
Among others, I observed this in my own brain during ayahuasca EEG postdoc back in 2013 ๐ฟ๐ง
Systemic model centered on thalamo-cortical connectivity
@AnnaCiaunica will enjoy seeing bodily self experiences included
Vollenweider concluding with recent model developed with @KatrinPreller ๐ฉโ๐ฌ ๐จ๐ญ Amazing work you two and team, so much effort for so long! ๐๐๐๐๐
Gabriella Gobbi now from @McGillNBPU speaking about translational issues, or how do ๐๐ โ๏ธ๐ถโโ๏ธ๐ถโโ๏ธresearch interelates
LSD shown to increase sociability in mice.
Ask ravers about it ๐
Optogenetic manipulation of prefrontal cortex ๐ can inhibit psychedelic-induced sociability
Gobbi's recommendation seem to be low-micro dose therapeutic regimes, yet with psychotherapy. Thank you for the work @McGillNBPU lab!
Now @zenbrainest taking us into the fascinating nanometer scales of drug-receptor binding interactions
Fascinating drug-receptor binding maps evolving.
How do we make sense of this kind of data and the more simplistic focus on 5HT2A receptor? ๐ค
320 GPCRs ๐คฏ Bryan Roth data blows my mind
Psilocin dopaminergic effects...
After all, would there be so much enthusiasm without good old reinforcing dopamine? ๐คฃ
Now Clinton Canal with an important question...
Another way to frame it ๐คฃ
Now Scott Thompson @sthom003 on more preclinical and mechanisms
What are 5HT2A receptors actually necessary for?
Now back to humans with @GitteKnudsen2 ๐ฉ๐ฐ with new in vivo imaging
Third and last session of #psychedelics@NIH ๐บ๐ฒ workshop starting now, looking at how to optimize clinical trials design and how to get these treatments approved ๐งต
Starting with Ido @hartogsohn ๐ฎ๐ฑ on psychedelic set and setting theory
Important Q โ
Do we have an (excessively) costly and complicated drug regulation apparatus?
Overcoming #EpistemicInjustices in the biomedical study of #ayahuasca: Towards #ethical and sustainable #regulation. New paper for โCultural context and ethical issues in the therapeutic use of psychedelicsโ special issue of Transcultural Psychiatry ๐งต1/
We (me and non-tweeter ๐ง๐ท PhD lawyer Konstantin Gerber) reviewed 4 decades of biomedical research about the sacred and ancient vine of the Amazon, documenting how biomedicine systematically commits a specific kind of injustice: against indigenous people as givers of knowledge. 2/
The powerful concept of epistemic injustice was introduced 15 years ago by Miranda Fricker (University of Oxford) and greatly helped us frame and analyse some past and current trends in ayahuasca research, which is also important to psychedelic science in general. 3/
1/16 THREAD๐งต3 years ago I proposed that #Psychedelic-Assisted Psychotherapy (PAP) is a #ParadigmShift in psychiatry. The paper has been viewed almost 80k times around the globe and sits at the top 1% views/downloads and top 8% citations of the whole @FrontiersIn journal series.
2/16 Published in the special issue โPsychedelic Drug Research in the 21st Centuryโ it has 82 citations at Google Scholar and was included in one slide by Javier Muรฑiz, from the FDAโs division of psychiatry, at his ISRP lecture in Oct/2019 frontiersin.org/articles/10.33โฆ
3/16 My perspective on the psychedelic impact on psychiatric research and development was based on Prof. @rose_nikolas useful critique of the current situation in psychiatry as a triple crisis cambridge.org/core/journals/โฆ